Reportstack is one of the largest online libraries of market research publications. We are the fastest growing and most preferred provider of business intelligence in the market today. We partner with the world's top publishers and research houses to bring to you expert analysis, accurate data and market information along with the best customer support and user experience. For more details, please visit www.reportstack.com
Thursday, 11 May 2017
Market Review on Home Innovation and Clinical Trial Tracking Factbook 2017
Back to Report Store Home Innovation and Clinical Trial Tracking Factbook 2017: An Assessment of the Pharmaceutical Pipeline is a new market research publication announced by Reportstack. This report is a comprehensive, granular analysis of the 25,522 products currently in the pharmaceutical industry pipeline, from the Discovery stage through to Pre-registration and split into therapy areas and key indications. This pipeline is also benchmarked against its size across each segment compared to 2015 and 2016, and an assessment of the level of first-in-class innovation is provided. In addition, a detailed contextual analysis of the key drivers of this pipeline is provided, in addition to an assessment of companies present in the pipeline and historical deal value and volume.
Innovation, particularly the development of new products, is a crucial element of the pharmaceutical industry. The market is highly research-intensive, being deeply reliant on a high level of R&D investment and a strong product pipeline to maintain growth and ensure long-term revenue generation. Without successful innovation, which can be broadly defined as the market launch of novel therapeutic molecules that cost-effectively treat or cure diseases, the industry would face a substantial long-term decline in revenue.
A particular focus of this report is placed on analysis of the development of innovative drugs, specifically first-in-class innovation. Over recent decades, in addition to an increase in the yearly number of new chemical entity approvals by the FDA, the number and proportion of these approvals that were first-in-class at the time of approval have also increased. The proportion of first-in-class approvals has increased steadily each year since 1994, with the exception of the years 2005–2008, when the proportion was relatively high. Scope
What is the current size and composition of the pharmaceutical industry pipeline and how has it changed in the last two years? What can we learn from this?
The largest therapy area, by a substantial margin, is oncology, and, with growth in the pipeline sizes for all major oncology indications since Q1 2015, this trend appears set to continue. Why is this the case?
What is the overall advantage for companies including first-in-class product developments in their pipeline portfolio, rather than opting for better-characterized established molecular targets?
What factors have been driving the increasing number of first-in-class product approvals over recent decades?
Historically, what has the risk of clinical trial attrition been across each therapy area and molecule type in the pharmaceutical industry? How long have their associated clinical trials been and how many patients, on average, were recruited?
Reasons To Buy
Achieve an up-to-date understanding of the landscape of the overall pharmaceutical pipeline, on both a broad and granular level; this also provides a highly accessible reference which is useful in any pharmaceutical strategic decision making process
Benchmark key therapy areas and indications in terms of the number of pipeline products and level of innovation, and assess one’s own strategic positioning against this backdrop
Understand the contemporary role and importance of radical and incremental innovation within the various disease areas and indications
Make key decisions about the role of innovation within one’s own pipeline portfolio
Understand and benchmark the risk of attrition, clinical trial duration and size across the pharmaceutical industry